Clinical Trials Browser

OTHER × Interventional × enzalutamide × Clear all

NCT06576037 2026-04-16

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Phase 1 Recruiting

Other solid neoplasm

Solid Tumor

NCT06616155 2026-04-13

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06632977 2026-04-07

PREDICT

Phase 2 Recruiting

Prostatic Neoplasms

NCT04363164 2026-04-06

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Phase 2 Recruiting

Castration Resistant Metastatic Prostate Cancer

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03674814 2026-03-31

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT06457919 2026-03-24

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT05751941 2026-03-16

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

Pathologic Complete Response, Neoplasm, Residual

NCT05726292 2026-03-04

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT05700903 2026-03-02

ARCH

Phase 4 Completed

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT03344211 2026-02-27

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06099769 2026-02-25

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT01885949 2026-02-24

Tivozanib + Enzalutamide in Adv Prostate Cancer

Phase 2 Terminated

5 enrolled 7 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 1/2 Active not recruiting

37 enrolled 10 charts

Prostatic Neoplasms

NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Phase 4 Active not recruiting

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT05683964 2026-02-13

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Phase EARLY_PHASE1 Active not recruiting

Prostatic Neoplasms

NCT02749903 2026-02-11

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Phase 2 Active not recruiting

46 enrolled 11 charts

Salivary Cancer

NCT05730712 2026-02-06

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT04455750 2026-02-05

CASPAR

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03246347 2026-01-23

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Phase 2 Active not recruiting

40 enrolled 12 charts

Prostatic Neoplasms

NCT03556904 2026-01-15

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Phase 2 Completed

14 enrolled 16 charts

Prostatic Neoplasms

NCT06059118 2026-01-14

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

Phase 2 Active not recruiting

188 enrolled 25 charts

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

Phase 2 Recruiting

Prostatic Neoplasms

NCT04655365 2025-12-23

PROSTEP-002

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05873192 2025-12-23

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT02452008 2025-12-19

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02312557 2025-12-03

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Phase 2 Active not recruiting

58 enrolled 13 charts

Prostatic Neoplasms

NCT02023463 2025-11-25

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Phase 1/2 Recruiting

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05743621 2025-11-21

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT05037500 2025-11-12

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT03734653 2025-11-06

Testosterone Therapy in Castration Resistant Prostate Cancer

Phase EARLY_PHASE1 Completed

Prostatic Neoplasms

NCT04335682 2025-11-04

ARACOG

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06844383 2025-10-29

TALENT

Phase 2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT02203695 2025-10-28

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

Phase 2 Completed

86 enrolled 13 charts

Adenocarcinoma of the Prostate

NCT06499870 2025-10-21

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Phase 2 Recruiting

Prostate Adenocarcinoma

NCT05081193 2025-09-22

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT06922318 2025-09-17

The COSMYC Trial (COmbined Suppression of MYC)

Phase 2 Recruiting

Prostatic Neoplasms

NCT05733351 2025-09-15

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT05011188 2025-08-27

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT04015622 2025-08-20

PROTRACT

Phase 2 Active not recruiting

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT01990196 2025-08-17

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05057013 2025-08-11

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT04471974 2025-07-22

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02955394 2025-07-09

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

Phase 2 Active not recruiting

61 enrolled 12 charts

Breast Neoplasms

NCT02750358 2025-06-22

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms